Nutex Health Inc.
For the period ended Mar 13, 2026. Filed Mar 13, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Mar 13, 2026 · Filed Mar 13, 2026
Use the contents to explore the available documents and sections.
Contents
Pay Versus Performance
The following Pay Versus Performance table summarizes compensation values reported in the Summary Compensation Table for our NEOs, as compared to “compensation actually paid” and the company’s financial performance for the years ended December 31, 2025, 2024, and 2023. This section also contains graphical disclosures of the pay versus performance relationship based on the information in the Pay Versus Performance Table.
| Year · Summary Compensation Table Total for PEO · Compensation Actually Paid to PEO(1)(5) · Average Summary Compensation Table Total for Non-PEO NEOs · Average Compensation Actually Paid to Non-PEO NEOs(1)(5) · Value of Initial Fixed $100 Investment Based On: · Net Income(4) · Adjusted EBITDA(4) | ||||||||
|---|---|---|---|---|---|---|---|---|
| Total Shareholder Return(2) · Peer Group Total Shareholder Return (NASDAQ US Benchmark Health Care Total Return Index) (3) | ||||||||
| 2025 | $1,938,970 | $4,602,970 | $787,807 | $1,429,454 | $57.76 | $122.07 | $70,789 | $259,565 |
| 2024 | $1,162,214 | $1,556,564 | $912,225 | $1,104,395 | $11.12 | $106.45 | $52,097 | $102,774 |
| 2023 | $1,020,395 | $1,020,395 | $577,386 | $586,616 | $9.47 | $102.96 | ($45,786) | ($5,830) |
| Year | PEO | Non-PEO NEOs |
| 2025 | Thomas T. Vo | Warren Hosseinion; Jon Bates; Wesley Bamburg; Joshua DeTillio; Michael Chang |
| 2024 | Thomas T. Vo | Warren Hosseinion; Jon Bates; Joshua DeTillio |
| 2023 | Thomas T. Vo | Warren Hosseinion; Jon Bates |
(1)Amounts represent compensation actually paid (as determined under applicable SEC regulations and described below) to our principal executive officer, or “PEO”, and the average compensation actually paid to our remaining NEOs for the relevant fiscal year, which includes the individuals indicated in the table below for each fiscal year:
(2)For purposes of this Pay Versus Performance disclosure, cumulative Total Shareholder Return is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between Nutex Health’s share price at the end and the beginning of the measurement period, by the share price at the beginning of the measurement period. All information set forth in the table above is adjusted for the Company’s 2024 reverse stock splits.
(3)For the relevant fiscal year, represents the cumulative TSR of the NASDAQ US Benchmark Health Care Total Return Index (NQUSB20T).
(4)Dollars in thousands.
(5)Compensation Actually Paid to our NEOs represents the “Total” compensation reported in the Summary Compensation Table for the applicable fiscal year, adjusted as follows:
| Adjustments | PEO: Thomas T. Vo | Average non-PEO NEOs |
|---|---|---|
| As Reported Summary Compensation Table Total | $1,938,970 | $787,807 |
| (-) Grant Date Fair Value of Stock Awards Granted in FY | 411,500 | 160,493 |
| (+) Awards granted in CFY that are outstanding and unvested as of end of CFY | 1,646,200 | 446,153 |
| (+) Awards that are granted and vest in the same CFY | — | — |
| (+) Prior year awards outstanding and unvested as of end of CFY | 1,329,300 | 347,000 |
| (+) Prior year awards that vest in CFY | 100,000 | 35,924 |
| (-) Prior year awards that fail to meet vesting conditions during CFY | — | 26,937 |
| (+) Dividends or other earnings paid on all awards in CFY prior to vesting date | — | — |
| (-) Change in Pension Value and Non-Qualified Deferred Compensation Earnings | — | — |
| (+) Pension Adjustment | — | — |
| Compensation actually paid | $4,602,970 | $1,429,454 |
| FY = Fiscal Year | ||
| CFY = Covered Fiscal Year | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.